Can [F-18]afatinib PET/CT be used in identifying NSCLC patients with different EGFR mutational status: tracer quantification and assessment of tumor uptake

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of Nuclear Medicine
Volume60
Publication statusPublished - 1 May 2019

Cite this

@article{d5d6edc958d744d2b9a156f2c4a9adc5,
title = "Can [F-18]afatinib PET/CT be used in identifying NSCLC patients with different EGFR mutational status: tracer quantification and assessment of tumor uptake",
author = "{van de Stadt}, Eveline and Maqsood Yaqub and Alex Poot and Robert Schuit and Idris Bahce and E. Smit and Harry Hendrikse",
year = "2019",
month = "5",
day = "1",
language = "English",
volume = "60",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",

}

TY - JOUR

T1 - Can [F-18]afatinib PET/CT be used in identifying NSCLC patients with different EGFR mutational status: tracer quantification and assessment of tumor uptake

AU - van de Stadt, Eveline

AU - Yaqub, Maqsood

AU - Poot, Alex

AU - Schuit, Robert

AU - Bahce, Idris

AU - Smit, E.

AU - Hendrikse, Harry

PY - 2019/5/1

Y1 - 2019/5/1

M3 - Meeting Abstract

VL - 60

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

ER -